Other languages Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
6.8 ^USD	+1.49%		-0.29%	-24.36%

May. 07	Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	MT
May. 06	Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	Apr. 24
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	Apr. 03
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	Mar. 11
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	Mar. 11
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	Feb. 23
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy	Feb. 23
Travere drug for rare kidney condition recommended for EU approval	Feb. 23
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 26
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy	Jan. 26
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations	Jan. 25
Travere Therapeutics Expects $40 Million in Q4 Net Product Sales	Jan. 08
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 08
Travere Therapeutics, Inc. Announces Program Updates and Anticipated 2024 Milestones	Jan. 08
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria	Dec. 14
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Dec. 05
Sector Update: Health Care	Dec. 05
Travere Therapeutics Says Pre-NDA Meeting With FDA for IgA Nephropathy Drug 'Successful'; Plans 20% Job Cut; Shares Jump Pre-Bell	Dec. 05
Travere Therapeutics, Inc. Completes Successful Pre-NDA Meeting for FILSPARI in IgAN	Dec. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Other languages

Filters